PE20081186A1 - Metodos y composiciones para el tratamiento de enfermedades alergicas - Google Patents
Metodos y composiciones para el tratamiento de enfermedades alergicasInfo
- Publication number
- PE20081186A1 PE20081186A1 PE2007000030A PE2007000030A PE20081186A1 PE 20081186 A1 PE20081186 A1 PE 20081186A1 PE 2007000030 A PE2007000030 A PE 2007000030A PE 2007000030 A PE2007000030 A PE 2007000030A PE 20081186 A1 PE20081186 A1 PE 20081186A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- treatment
- compositions
- methods
- allergic diseases
- Prior art date
Links
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN ANTICUERPO ANTAGONISTA DEL RECEPTOR DE LINFOPOYETINA ESTROMAL TIMICA HUMANA (TSLP) QUE COMPRENDE: A) UNA SECUENCIA DE REGION VARIABLE DE CADENA PESADA DE LA SEQ ID Nº:5; B) UNA SECUENCIA DE REGION VARIABLE DE CADENA LIGERA DE LA SEQ ID Nº:6. DICHO ANTICUERPO HUMANIZADO DE UNA SOLA CADENA ES DEL ISOTIPO IgG1 O IgG4 QUE COMPRENDE UNA SECUENCIA DE LA REGION DETERMINANTE DE COMPLEMENTARIEDAD (CDR) DE CADENA PESADA DE LA SEQ ID Nº: 7, SEQ ID Nº: 8 O SEQ ID Nº: 9; O UNA SECUENCIA DE LA REGION DETERMINANTE DE COMPLEMENTARIEDAD (CDR) DE CADENA LIGERA DE SEQ ID Nº: 10, SEQ ID Nº: 11 O SEQ ID Nº: 12. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA SIENDO UTIL EN EL TRATAMIENTO DE ASMA, DERMATITIS ATOPICA, RINITIS ALERGICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75962506P | 2006-01-13 | 2006-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081186A1 true PE20081186A1 (es) | 2008-09-24 |
Family
ID=38541770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000030A PE20081186A1 (es) | 2006-01-13 | 2007-01-11 | Metodos y composiciones para el tratamiento de enfermedades alergicas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8097705B2 (es) |
| EP (2) | EP1981912A2 (es) |
| JP (1) | JP5258578B2 (es) |
| KR (1) | KR101383472B1 (es) |
| CN (1) | CN101370831B (es) |
| AR (1) | AR058983A1 (es) |
| AU (1) | AU2007230868B2 (es) |
| BR (1) | BRPI0706530A2 (es) |
| CA (1) | CA2635599C (es) |
| PE (1) | PE20081186A1 (es) |
| RU (1) | RU2486202C2 (es) |
| TW (1) | TWI401261B (es) |
| WO (1) | WO2007112146A2 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029581A1 (en) | 1998-11-13 | 2000-05-25 | Immunex Corporation | Human tslp dna and polypeptides |
| CA2413673C (en) * | 2000-06-28 | 2018-01-09 | Amgen Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
| US7288633B2 (en) | 2001-07-23 | 2007-10-30 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
| KR20100034015A (ko) * | 2007-06-20 | 2010-03-31 | 아이알엠 엘엘씨 | 알레르기 질환 치료를 위한 방법 및 조성물 |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| CA2713935C (en) * | 2008-02-07 | 2016-11-01 | Schering Corporation | Engineered anti-tslpr antibodies |
| EP2213682A1 (en) | 2009-01-30 | 2010-08-04 | Institut Curie | TSLP promotes immune evasion and persistence of viruses |
| EP2427216B1 (en) * | 2009-05-06 | 2019-02-20 | Biotest AG | Uses of immunoconjugates targeting cd138 |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| CN104098696A (zh) * | 2013-04-07 | 2014-10-15 | 中美华世通生物医药科技（武汉）有限公司 | 一种抗血管内皮生长因子的单克隆抗体 |
| ES2730978T3 (es) * | 2013-08-09 | 2019-11-13 | Astellas Pharma Inc | Anticuerpo anti-receptor de TSLP humana nuevo |
| CN104804088A (zh) * | 2014-01-26 | 2015-07-29 | 中美华世通生物医药科技（武汉）有限公司 | 一种抗vegf的单克隆抗体 |
| CN104804087A (zh) * | 2014-01-26 | 2015-07-29 | 中美华世通生物医药科技（武汉）有限公司 | 一种抗血管内皮生长因子的单克隆抗体16-3 |
| JP7179464B2 (ja) | 2015-01-20 | 2022-11-29 | アイジーエム バイオサイエンシズ インコーポレイテッド | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| AU2016318158B2 (en) * | 2015-09-04 | 2022-09-15 | Health Research, Inc. | Anti-survivin antibodies for cancer therapy |
| HUE053914T2 (hu) * | 2015-09-09 | 2021-07-28 | Novartis Ag | Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások |
| TN2018000076A1 (en) * | 2015-09-09 | 2019-07-08 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
| CN108430507B (zh) | 2015-12-18 | 2022-08-02 | 安斯泰来制药株式会社 | 含有抗人tslp受体抗体的药物组合物 |
| US20190093164A1 (en) * | 2016-02-22 | 2019-03-28 | National University Corporation Chiba University | Biomarker for diagnosis of allergic rhinitis |
| EA202090427A1 (ru) * | 2017-08-16 | 2020-06-08 | МЕДИММЬЮН, ЭлЭлСи | Композиции и способы лечения атопического дерматита и выбора лечения |
| CN109988759A (zh) * | 2017-12-29 | 2019-07-09 | 上海细胞治疗研究院 | 一种在t细胞中具有高转录活性的嵌合启动子 |
| CN111196850B (zh) * | 2020-02-07 | 2020-10-30 | 北京汇智和源生物技术有限公司 | 人胸腺基质淋巴细胞生成素单克隆抗体及其应用 |
| CN113069543B (zh) * | 2021-06-07 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物 |
| US20240360233A1 (en) | 2021-08-27 | 2024-10-31 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
| CN117209604B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202432601A (zh) | 2022-11-07 | 2024-08-16 | 美商上游生物公司 | 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993016185A2 (en) * | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| WO2000029581A1 (en) * | 1998-11-13 | 2000-05-25 | Immunex Corporation | Human tslp dna and polypeptides |
| CA2413673C (en) * | 2000-06-28 | 2018-01-09 | Amgen Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
| ES2357225T3 (es) * | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| US7261890B2 (en) * | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| JP2008507476A (ja) * | 2004-04-29 | 2008-03-13 | 大塚製薬株式会社 | 糖タンパク質ｖｉに特異的な抗体及びこれらの抗体を産生する方法 |
| CA2577631A1 (en) | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
-
2007
- 2007-01-11 PE PE2007000030A patent/PE20081186A1/es not_active Application Discontinuation
- 2007-01-11 AU AU2007230868A patent/AU2007230868B2/en not_active Ceased
- 2007-01-11 CN CN2007800030912A patent/CN101370831B/zh not_active Expired - Fee Related
- 2007-01-11 US US12/160,868 patent/US8097705B2/en not_active Expired - Fee Related
- 2007-01-11 JP JP2008550514A patent/JP5258578B2/ja not_active Expired - Fee Related
- 2007-01-11 KR KR1020087016912A patent/KR101383472B1/ko not_active IP Right Cessation
- 2007-01-11 EP EP07756333A patent/EP1981912A2/en not_active Withdrawn
- 2007-01-11 WO PCT/US2007/060379 patent/WO2007112146A2/en active Application Filing
- 2007-01-11 EP EP10180544A patent/EP2287196A3/en not_active Withdrawn
- 2007-01-11 CA CA2635599A patent/CA2635599C/en not_active Expired - Fee Related
- 2007-01-11 AR ARP070100117A patent/AR058983A1/es not_active Application Discontinuation
- 2007-01-11 BR BRPI0706530-2A patent/BRPI0706530A2/pt not_active IP Right Cessation
- 2007-01-11 RU RU2008132968/10A patent/RU2486202C2/ru not_active IP Right Cessation
- 2007-01-12 TW TW096101195A patent/TWI401261B/zh not_active IP Right Cessation
-
2011
- 2011-09-23 US US13/242,418 patent/US20120027756A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007230868B2 (en) | 2012-02-02 |
| TWI401261B (zh) | 2013-07-11 |
| KR20080090418A (ko) | 2008-10-08 |
| CN101370831A (zh) | 2009-02-18 |
| EP2287196A2 (en) | 2011-02-23 |
| US8097705B2 (en) | 2012-01-17 |
| JP2009523426A (ja) | 2009-06-25 |
| RU2008132968A (ru) | 2010-02-20 |
| US20120027756A1 (en) | 2012-02-02 |
| RU2486202C2 (ru) | 2013-06-27 |
| JP5258578B2 (ja) | 2013-08-07 |
| AU2007230868A1 (en) | 2007-10-04 |
| US20090286312A1 (en) | 2009-11-19 |
| EP2287196A3 (en) | 2011-05-04 |
| KR101383472B1 (ko) | 2014-04-08 |
| WO2007112146A2 (en) | 2007-10-04 |
| TW200736275A (en) | 2007-10-01 |
| BRPI0706530A2 (pt) | 2011-03-29 |
| AR058983A1 (es) | 2008-03-05 |
| EP1981912A2 (en) | 2008-10-22 |
| CN101370831B (zh) | 2013-06-19 |
| WO2007112146A3 (en) | 2008-06-05 |
| CA2635599A1 (en) | 2007-10-04 |
| CA2635599C (en) | 2014-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081186A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| NL301196I2 (nl) | inebilizumab | |
| WO2016081746A3 (en) | Antibodies comprising modified heavy constant regions | |
| MX2024004322A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| PE20090294A1 (es) | Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| PE20140814A1 (es) | Anticuerpos contra la angiopoyetina 2 humana | |
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| DE602006017690D1 (de) | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung | |
| TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
| CL2007000478A1 (es) | Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t | |
| MY153893A (en) | Antibodies against human il17 and uses thereof | |
| EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| PE20081899A1 (es) | Anticuerpos anti-ige | |
| AR082163A1 (es) | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos | |
| MX2011009312A (es) | Formulaciones de anticuerpos humanizados anti-cd19. | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |